A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
Acimtamig (AFM13)治疗CD30阳性、复发或难治性外周T细胞淋巴瘤患者的II期研究
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-1913
Kim, Won Seog; Shortt, Jake; Zinzani, Pier Luigi; Mikhailova, Natalia; Radeski, Dejan; Ribrag, Vincent; Domingo Domenech, Eva; Sawas, Ahmed; Alexis, Karenza; Emig, Michael; Elbadri, Riham; Hajela, Pallavi; Ravenstijn, Paulien; Pinto, Sheena; Garcia, Linta; Overesch, Andre; Pietzko, Kerstin; Horwitz, Steven
T细胞
淋巴瘤
CD30
CD3
T细胞
细胞生物学
免疫/内分泌